Intrathecal drug delivery systems for noncancer pain: a health technology assessment
Health Quality Ontario
Record ID 32016000550
English
Authors' recommendations:
Current evidence does not establish (or rule out) superiority or cost-effectiveness of intrathecal drug delivery systems for managing chronic refractory nonmalignant pain. The budget impact of funding intrathecal drug delivery systems would be between $1.5 and $5.0 million per year.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hqontario.ca/Portals/0/Documents/eds/ohtas/eba-noncancer-pain-1602-en.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Analgesics
- Drug Delivery Systems
- Pain
- Technology Assessment, Biomedical
Contact
Organisation Name:
Health Quality Ontario
Contact Address:
Evidence Development and Standards, Health Quality Ontario, 130 Bloor Street West, 10th floor, Toronto, Ontario Canada M5S 1N5
Contact Name:
EDSinfo@hqontario.ca
Contact Email:
OH-HQO_hta-reg@ontariohealth.ca
Copyright:
Health Quality Ontario (HQO)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.